2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2222A
    DX600 TFA 99.20%
    DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 TFA exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity.
    DX600 TFA
  • HY-P2807A
    Lactate Dehydrogenase (LDH), Porcine Heart 9001-60-9
    Lactate Dehydrogenase (LDH), Porcine Heart, is an isoenzyme of lactate dehydrogenase derived from porcine heart. Lactate Dehydrogenase (LDH), Porcine Heart, is primarily used in life science research, tissue damage diagnosis, and as an enzyme marker.
    Lactate Dehydrogenase (LDH), Porcine Heart
  • HY-P2812A
    Phospholipase D, peanut 9001-87-0
    Phospholipase D, peanut is a phospholipase D (EC 3.1.4.4) of the PLD superfamily found in peanuts, acting as a phosphodiesterase and signaling enzyme with activity toward phosphatidylcholine. Phospholipase D hydrolyzes phosphatidylcholine to phosphatidic acid and choline, and catalyzes transphosphatidylation reactions. Phospholipase D can be used for the research of myocardial disease, ischemic heart disease, congestive heart failure, diabetic cardiomyopathy, cardiac hypertrophy, vascular abnormalities, breast cancer, gastric cancer, renal cancer, colorectal cancer.
    Phospholipase D, peanut
  • HY-P3446A
    Big Gastrin I (human) TFA
    Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases.
    Big Gastrin I (human) TFA
  • HY-P5142A
    ω-Hexatoxin-Hv1a TFA
    ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca2+ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons.
    ω-Hexatoxin-Hv1a TFA
  • HY-P9940A
    Emicizumab (Anti-F9 & Factor IX) 99.69%
    Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research.
    Emicizumab (Anti-F9 & Factor IX)
  • HY-U00044
    Anipamil 83200-10-6 99.34%
    Anipamil is a long-acting calcium channel blocker, used for the treatment of cardiovascular disease.
    Anipamil
  • HY-U00208
    Prinoxodan 111786-07-3 99.83%
    Prinoxodan (RGW2938) is a phosphodiesterase inhibitor.
    Prinoxodan
  • HY-100573S
    Necrosulfonamide-d4 1795144-22-7 99.65%
    Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
    Necrosulfonamide-d4
  • HY-100795A
    Pirmenol hydrochloride 61477-94-9 99.34%
    Pirmenol ((±)-Pirmenol) hydrochloride is an orally active antiarrhythmic agent. Pirmenol hydrochloride inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol hydrochloride can be used in the research of cardiovascular disease, such as atrial fibrillation.
    Pirmenol hydrochloride
  • HY-101436A
    Sematilide hydrochloride 101526-62-9 99.85%
    Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
    Sematilide hydrochloride
  • HY-105084A
    Lubeluzole dihydrochloride 144665-09-8 99.00%
    Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole dihydrochloride is the S-isomer of benzothiazole derivative. Lubeluzole dihydrochloride can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole dihydrochloride exhibits anti-ischemic and neuroprotective effects. Lubeluzole dihydrochloride also shows anti-bacterial and anti-diarrheal potential. Lubeluzole dihydrochloride can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole dihydrochloride can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole dihydrochloride can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian.
    Lubeluzole dihydrochloride
  • HY-106912A
    L-706000 free base 161799-18-4 98%
    L-706000 (MK 499) free base is a potent hERG channel blocker with an IC50 of 32 nM. L-706000 free base is a class III antiarrhythmic agent that can be used for the study of malignant ventricular tachyarrhythmias.
    L-706000 free base
  • HY-106961A
    (Z)-ONO 1301 153814-74-5 98.13%
    (Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig.
    (Z)-ONO 1301
  • HY-107542R
    Oleoylethanolamide (Standard) 111-58-0 99.86%
    Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
    Oleoylethanolamide (Standard)
  • HY-112499R
    Menaquinone-7 (Standard) 2124-57-4 98.27%
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS).
    Menaquinone-7 (Standard)
  • HY-113110A
    Cysteinylglycine TFA 1100364-95-1 ≥98.0%
    Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc[1][2][3][4].
    Cysteinylglycine TFA
  • HY-113216R
    Asymmetric dimethylarginine (Standard) 30315-93-6 99.85%
    Hesperetin (Standard) is the analytical standard of Hesperetin. This product is intended for research and analytical applications. Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity. Hesperetin regulates apoptosis.
    Asymmetric dimethylarginine (Standard)
  • HY-113456S
    Leukotriene D4-d5 1240398-17-7 98.4%
    Leukotriene D4-d5 is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.
    Leukotriene D4-d5
  • HY-114164G
    Murine Thrombin 9002-04-4
    Murine Thrombin is a murine serine protease that plays a central role in blood coagulation. Murine Thrombin stimulates macrophages to polarize into a unique phenotype characterized by anti-inflammatory and pro-repair properties. Murine Thrombin activates PAR1, induces the production of MCP-1, MMP3 and VEGF in mouse intervertebral discs, and causes degradation of the cartilage matrix and destruction of intervertebral disc structure. Murine Thrombin activity increases significantly in paraoxon-induced status epilepticus.
    Murine Thrombin
Cat. No. Product Name / Synonyms Application Reactivity